Overview
TGTX market data
Price History
TGTX price chart · 1M
- O
- 54.73
- H
- 55.97
- L
- 54.37
- C
- 55.71
- Vol
- 68,589.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $54.73
- Previous Close
- $54.98
- Day High
- $55.97
- Day Low
- $54.37
- 52 Week High
- $59.30
- 52 Week Low
- $33.27
- 7 Day Return
- +10.18%
- 30 Day Return
- +1.54%
- 90 Day Return
- +46.86%
- 1 Year Return
- +65.85%
- Daily Notional Volume
- $3.8M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 16.62 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.77 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.80 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 55.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $26.76 – $59.30 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $7.3B · P/B 21.07 · P/S 9.18.
Company News
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On FridayBenzinga · Aug 21, 2026, 2:18 PM
Watching TG Therapeutics; Traders Speculate Multiple Parties Interested To Acquire TG TherapeuticsBenzinga · Aug 21, 2026, 1:47 PM
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72Benzinga · Aug 7, 2026, 4:51 PM
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.Benzinga · Aug 3, 2026, 2:12 PM
8-K filing — TG THERAPEUTICS, INC. (TGTX)SEC EDGAR · Aug 3, 2026, 11:05 AM
TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M EstBenzinga · Aug 3, 2026, 11:00 AM
TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M EstimateBenzinga · Aug 3, 2026, 11:00 AM
B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $86Benzinga · Jul 27, 2026, 5:39 PM
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmGlobenewswire Inc · Jul 17, 2026, 11:15 AM
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $77Benzinga · Jul 13, 2026, 9:59 AM